Search Bar & Filters
Found 86 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tenapanor in adults with Chronic Idiopathic Constipation CIC. This study is a 26-week, multi-center, randomized, double-blind, placebo-controlled trial followed by a 4-week treatment-free safety follow-up period. It aims to compare three different doses of tenapanor with a placebo taken twice daily to assess their impact on constipation symptoms. The study includes a 2-week screening period to confirm eligibility, followed by a 26-week randomized treatment period where patients receive either 5 mg, 25 mg, or 50 mg of tenapanor twice daily, or a matching placebo. Patients record their constipation symptoms daily in an electronic diary. After the treatment period, there is a 4-week safety follow-up without treatment to monitor any adverse effects. Participants will have regular visits every 2 to 6 weeks for safety checks including medical assessments, vital signs, ECG, and lab tests. Their symptom diaries will be reviewed throughout the study. The main outcome measured is the durable complete spontaneous bowel movements response at 12 weeks. Secondary outcomes include changes in bowel movement frequency, stool consistency, and straining. The total study duration is approximately 32 weeks including all phases.
Actively Recruiting
Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects vision. This study aims to learn if a medicine called tiespectus also known as MK-8748 or EYE201 can treat NVAMD as well as the standard treatment called aflibercept. The trial is a pivotal Phase 23 study that compares these treatments in people newly diagnosed with NVAMD. Participants are randomly assigned to one of three groups one group receives a low dose of tiespectus, another receives a high dose of tiespectus, and the third group receives aflibercept. Those in the tiespectus groups get three initial injections every 4 weeks, then continue injections every 8 weeks until week 48, followed by treatments at intervals based on their individual response up to week 92. The aflibercept group receives three initial injections followed by injections every 8 weeks until week 92. During the study, participants are regularly assessed for changes in their best-corrected visual acuity using ETDRS letters from baseline to one year. Other evaluations include eye imaging to measure retinal thickness and monitoring for any adverse events up to approximately 96 weeks. The study lasts over one year with ongoing visits to track treatment response and safety.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a community health intervention aimed at increasing lung cancer screening and tobacco treatment use among adults aged 50 to 80 who receive primary care at specific community health centers. Lung cancer screening with low-dose CT scans can reduce deaths but remains underused, especially in populations facing barriers to preventive care. The study is a pilot randomized controlled trial assessing how different navigator models impact screening uptake and tobacco treatment. Participants are randomly assigned to one of three groups enhanced usual care with educational materials and standard screening through their provider a multi-part intervention delivered by a community health worker or the same intervention delivered by a trained lay navigator. The intervention includes patient outreach, shared decision-making about screening, tobacco counseling, and help with logistical barriers to care. During the study, researchers will collect data monthly over about a year on recruitment, retention, intervention quality, and participant acceptability. They will also measure lung cancer screening referrals and completion, tobacco treatment use, and quit attempts. This pilot will help design a future larger trial to better understand how community health workers and lay navigators can support access to lung cancer screening and tobacco treatment.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a combined treatment using KarXT and KarX-EC in adults aged 55 to 90 years who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study is sponsored by Bristol-Myers Squibb and aims to address agitation symptoms in this population by comparing the study drugs against placebo. Participants have a confirmed Alzheimers diagnosis and agitation symptoms as defined by recognized criteria. Participants receive either the combined drugs KarXT and KarX-EC or a placebo, with doses given on specified days. The study is designed with parallel groups and maintains blinding to ensure unbiased results. This treatment period lasts 14 weeks, during which the effects on agitation and related symptoms are closely monitored. During the trial, participants and their caregivers attend regular visits to assess changes in agitation using established tools like the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association CMAI-IPA and other scales. Safety is monitored through adverse event tracking, physical exams, laboratory tests, vital signs, and electrocardiograms. The study also evaluates cognitive and behavioral changes up to 18 weeks, with caregivers playing a key role in reporting participant status and medication adherence.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the drug ozanimod RPC1063 in treating pediatric participants aged 2 to 17 years who have moderate to severe active ulcerative colitis UC. These participants have not responded adequately to standard treatments. The study is a combined Phase 23, randomized, double-blind trial aimed at achieving and maintaining clinical remission in this population. Participants will receive oral ozanimod at different dose levels as part of the study. The treatment involves specified doses given on specific days. The study includes two experimental groups receiving either a high or low dose of ozanimod. The trial will assess outcomes over various time points, including up to 70 weeks for pharmacokinetics and safety monitoring, and follow-up for adverse events up to 6 years. During the study, participants will be closely monitored through clinical assessments, endoscopic evaluations, and laboratory tests. Researchers will measure remission rates, clinical responses, symptomatic remission, corticosteroid-free remission, endoscopic improvement, and lymphocyte counts. Safety will be tracked by documenting adverse events and serious adverse events throughout the study and follow-up period. The primary outcome is the proportion of participants achieving clinical remission at Week 52.
Actively Recruiting
Researchers are evaluating the effects of experimental drugs pozelimab and cemdisiran in adults aged 50 to 85 with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD, a condition affecting central vision. The study aims to compare the progression rate of GA in patients treated with cemdisiran alone, pozelimab combined with cemdisiran, and a placebo, while also examining side effects, drug levels in the blood, and immune responses to the drugs. Participants are randomly assigned to one of three groups pozelimab plus cemdisiran, cemdisiran alone, or placebo. All treatments are given by subcutaneous injection. The study is double-masked and placebo-controlled, lasting up to 104 weeks for key outcome measures, with extended safety monitoring up to 296 weeks. The trial includes multiple visits for evaluations and treatments over this period. During the study, participants undergo detailed eye imaging using Fundus Autofluorescence to measure GA lesion growth, assessments of visual acuity, and contrast sensitivity tests at weeks 52 and 104. Blood samples are collected to measure drug concentrations and immune responses, including antibodies against the drugs. Safety is monitored throughout the study and during extended follow-up. Participants adherence to clinic visits and vaccinations is required for participation.
Actively Recruiting
Researchers are evaluating the efficacy and safety of azenosertib ZN-c3, an oral selective WEE1 inhibitor, in women with platinum-resistant, high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. This Phase 2 study focuses on patients whose tumors express Cyclin E1 protein, identified through a specialized assay. The study includes multiple parts, with Part 2 specifically enrolling Cyclin E1 positive patients to better understand the drugs impact in this subgroup. Participants receive azenosertib orally, following an intermittent dosing schedule of 400 mg once daily for 5 days, then 2 days off. Different dosing arms exist, including a 300 mg dose, all administered under careful monitoring. The study is randomized and open-label, with several parts completed and Part 2c actively enrolling. The treatment period and follow-up extend for up to approximately 12 months to assess various outcomes. During the study, participants undergo tumor testing, disease evaluation by standard imaging criteria RECIST v1.1, and monitoring of blood markers such as CA-125. Researchers track response rates, duration of response, progression-free survival, clinical benefit, and adverse events. Regular assessments ensure safety and treatment adherence. The total participation duration encompasses treatment and follow-up phases, with outcomes measured up to about one year after the last participant enrolls.
Actively Recruiting
Researchers are evaluating the efficacy and safety of brenipatide, given alongside standard of care, compared with a placebo plus standard of care, in delaying the worsening of symptoms in adults with bipolar disorder. This phase 2, randomized, double-blind study aims to better understand how brenipatide might help manage bipolar disorder symptoms over time. Participants receive either one of two doses of brenipatide or a placebo, both administered by subcutaneous injection, combined with their standard bipolar disorder treatment. The study includes three main periods a screening period lasting about one month, a treatment period lasting at least six months, and a follow-up period of about two months. Study participation may be shortened if symptoms worsen or if the participant chooses to withdraw. During the study, participants are asked to self-inject the study medication, keep electronic and paper diaries, and complete questionnaires. Researchers will monitor outcomes such as time to relapse, changes in disability, depression and mania scores, quality of life, patient impressions, body weight changes, and treatment-related antibody development. Safety and effectiveness measures will be collected throughout treatment and follow-up, with total participation lasting around nine months or less depending on individual circumstances.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of brenipatide compared to placebo in people with opioid use disorder OUD who are also receiving buprenorphine treatment, with or without naloxone. This Phase 2 study includes participants with mild to severe OUD and aims to assess abstinence from opioid use over a defined period. The study has two parts Part A involves a double-blind treatment phase followed by an open-label extension, while Part B includes only open-label treatment. Participants receive brenipatide or placebo by subcutaneous injection alongside buprenorphine administered under the tongue or in the cheek. Each participant enrolls in only one part, with treatment durations up to approximately 144 weeks in Part A and 116 weeks in Part B. Participants attend regular study visits for assessments, including urine drug screens and self-reports to measure opioid abstinence, adherence to buprenorphine, and changes in craving and quality of life. Other evaluations include monitoring for overdose events, healthcare utilization, body measurements, and blood pressure. Safety is tracked through laboratory tests and antibody monitoring, with the overall study lasting up to several years depending on enrollment timing.
Actively Recruiting
Researchers are evaluating a new medication called CX11 for people with type 2 diabetes who have not achieved good blood sugar control despite taking a steady dose of metformin, with or without an SGLT2 inhibitor, for at least 90 days. This phase 2 study involves multiple medical centers and aims to determine the effectiveness and safety of CX11 compared to placebo in adults aged 18 to 75 years with specific blood sugar and body weight criteria. Participants will be randomly assigned to one of six groups, each receiving either a different dose of CX11 tablets or a matching placebo once daily. The treatment period lasts 24 weeks, followed by a 2-week safety follow-up. Neither participants nor study staff will know which group the participant is in during the study, ensuring a double-blind design. Throughout the study, participants will undergo various assessments including blood sugar measurements like HbA1c and continuous glucose monitoring, body weight and blood pressure checks, and safety monitoring for adverse events. Blood samples will be taken at multiple time points to measure drug levels. The primary outcome is the change in HbA1c after 24 weeks of treatment. Total participation lasts approximately 26 weeks, including treatment and follow-up.
1-10 of 86
1